Investigational PPAR-delta Agonist for PBC Treatment and Race-Based Considerations for PBC Diagnosis: Conference Coverage of AASLD
Listen as Stuart C. Gordon, MD, FAASLD, discusses exciting new PBC data from AASLD 2023, including a late-breaking study of a PPAR-delta agonist and a study that explored racial differences as they relate to the presentation and diagnosis of PBC.
Decera Clinical Education Infectious Disease Podcast · Stuart C. Gordon MD FAASLD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.
In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including:
- A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acid
- A study that explored racial differences as they relate to the presentation and diagnosis of PBC
Presenter:
Stuart C. Gordon, MD, FAASLD
Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan
Link to commentary:
https://bit.ly/3GzRMt2
Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.